Duvelisib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Duvelisib |
| DrugBank ID | DB11952 |
| Brand Names (EU) | Copiktra |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.94% |
Approved Indication (EMA)
Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Hodgkins lymphoma | 99.94% | DL |
| 2 | myeloid leukemia | 99.94% | DL |
| 3 | follicular lymphoma | 99.92% | DL |
| 4 | acute lymphoblastic/lymphocytic leukemia | 99.91% | DL |
| 5 | chronic myelogenous leukemia, BCR-ABL1 positive | 99.91% | DL |
| 6 | Ewing sarcoma | 99.88% | DL |
| 7 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.87% | DL |
| 8 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.87% | DL |
| 9 | mantle cell lymphoma | 99.84% | DL |
| 10 | ganglioneuroblastoma (disease) | 99.82% | DL |
| 11 | B-cell neoplasm | 99.80% | DL |
| 12 | vertebral anomalies and variable endocrine and T-cell dysfunction | 99.80% | DL |
| 13 | retroperitoneal neoplasm | 99.80% | DL |
| 14 | Richter syndrome | 99.79% | DL |
| 15 | neuroblastoma | 99.78% | DL |
| 16 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | 99.73% | DL |
| 17 | neoplasm of mature B-cells | 99.73% | DL |
| 18 | small intestinal Burkitt lymphoma | 99.67% | DL |
| 19 | lymphoma, non-Hodgkin, familial | 99.66% | DL |
| 20 | thyroid gland mucosa-associated lymphoid tissue lymphoma | 99.66% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.